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Introduction and background
===========================

Depression is a serious mental health condition characterized by a persistently depressed mood and diminished interest in activities and can lead to severe functional impairment in daily life. In diagnosing depression, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders requires five or more symptoms to be present within a two-week period, with one of these symptoms being a depressed mood or anhedonia (loss of interest or pleasure). Secondary symptoms of major depression include changes in appetite and/or weight changes, sleep difficulties (insomnia or hypersomnia), psychomotor agitation or retardation, fatigue or loss of energy, diminished ability to think or concentrate, feelings of worthlessness or excessive guilt, and suicidal ideation. The lifetime prevalence of depression in the general population has been estimated to be 10% \[[@REF1]-[@REF2]\].

Major depressive disorder (MDD) is a highly prevalent psychiatric disorder with significant morbidity and mortality. Psychotherapy, medications, and their combination are often insufficient to control the symptoms of MDD, resulting in treatment-resistant depression (TRD). This leads to poor functional outcomes in patients, including increased unemployment, suicidal ideation, substance abuse, and unstable relationships. Transcranial magnetic stimulation (TMS) has been successful in treating patients with TRD. A literature review reported that the response rates to TMS range between 50% and 55%, and the remission rates range between 30% and 35% in patients with major depression \[[@REF3]\]. The dorsolateral prefrontal cortex (DLPFC) is the part of the brain that has been reported dysregulated in patients with major depression, resulting in symptoms consistent with this condition depression \[[@REF4]\]. TMS targets the pathophysiology of depression, using high-frequency electromagnetic induction over the left DLPFC to effectively treat the behavioral dysregulation in patients with major depression.

Review
======

TMS is an advanced treatment modality for patients with TRD, in which brief magnetic pulses are applied to the brain, leading to cortical stimulation. Repetitive TMS (rTMS) consists of the delivery of pulses in a repetitive fashion. TMS is a non-invasive technique, as it does not require craniotomy or seizure induction to stimulate nerve cells \[[@REF5]\]. Rather, TMS interconverts electrical and magnetic energy to induce electromagnetic phenomena. An electromagnetic coil is placed on the scalp, and an effective pulsatile magnetic field that depolarizes cortical neurons is generated for a brief duration of time. This forceful magnetic field is generated on the surface of the scalp, without any intrusion into the skin, muscles or bones, making its electrical stimulation electrodeless \[[@REF5]-[@REF6]\]. Levels of excitability of neuronal stimulation can be regulated, either by high (10 to 20 Hz) or low (1 Hz) frequency. The generated magnetic field is about 1.5 Tesla, similar in strength to that of magnetic resonance imaging \[[@REF7]\]. Patients being treated with TMS undergo five daily treatment sessions over three to six weeks, resulting in a total of 20 to 30 sessions during treatment.

High-frequency stimulation of the left DLPFC alleviates depressive symptoms, whereas low-frequency cortical stimulation of the right DLPFC helps to relieve the symptoms of both depression and anxiety. This was validated by a case series in which the effects of TMS on either side of the prefrontal cortex were evaluated in 16 healthy individuals aged 24 to 75 years. Patients who underwent stimulation of the left DLPFC showed a drop in salivary cortisol level in the morning. However, the results of this study were limited due to the small sample size and limited number of TMS sessions \[[@REF6]\]. Many randomized clinical trials have shown that daily TMS of the left prefrontal cortex was effective in treating depressive mood symptoms, with remission rates of 30% to 40% of cases. Similar to antidepressants, TMS resulted in sustained improvement in mood symptoms but with fewer side effects \[[@REF5],[@REF8]\].

Another randomized multicenter trial showed that this non-invasive treatment method had significant antidepressant effects with remission rates four-fold higher than placebo. A multicenter observational study involving 307 patients in a clinical setting showed that the depression severity scale decreased after treatment with TMS. Moreover, therapeutic responses were maintained in patients treated with TMS \[[@REF5],[@REF9]-[@REF10]\]. TMS was found to significantly improve all symptoms of depression on the Hamilton depression rating scale \[[@REF11]\]. Another randomized, controlled, multicenter, multiphase trial, performed at 23 sites worldwide, assessed the effects of TMS in patients diagnosed with MDD and free of the side effects of any antidepressant. This trial showed that patients who underwent TMS demonstrated clinically and statistically significant improvements on the Montgomery-Asberg Depression Rating Scale (MASDR) after four weeks; however, this outcome was similar to that observed in patients randomized to placebo \[[@REF5],[@REF12]\]. Another study provided descriptive evidence of the long-term therapeutic benefits of TMS and maintenance of benefits with post-TMS antidepressant therapy \[[@REF13]\].

The neurobiological phenomena underlying the effectiveness of TMS as an antidepressant are not well understood, although studies have suggested a correlation between cerebral metabolic activity and TMS effectiveness. This was validated by the results of TMS treatment in non-responders who exhibited hypoperfusion in the frontal cortex. A pilot study involving 15 medication-resistant patients demonstrated an increase in cerebral blood volume during TMS. Blood flow was measured at the beginning and end of each TMS session, with the frontal hemoglobin concentration (fHbC) found to be associated with treatment outcomes, in that increased fHbC during magnetic induction was inversely related to MASDR scores. This study was limited due to the small sample size and because cerebral blood flow was not measured in the middle of treatment with TMS \[[@REF14]-[@REF15]\]. Neuronal physiology that responds to TMS is of central importance, as repetitive stimulations increase synaptic plasticity, causing it to last longer even after stimulation ceases. This result is contrary to the decrease in synaptic strength observed in depression and may be attributed to the fact that fast rTMS (\> 10 Hz) results in neuronal excitation while slow rTMS (\< 1 Hz) has the reverse effects. Another study reported that daily sessions of TMS over the prefrontal cortex were found to increase cortical activity and reduce activity in distant areas; moreover, cerebral blood flow at the stimulation site decreased with increasing coil distance from the scalp to the outer cortex \[[@REF16]\]. As recommended, neuromodulation therapy via TMS is usually performed after failure of an antidepressant trial, with or without psychotherapy.

Magnetoencephalography has provided insights into the possible role of neuronal circuits in TMS-induced improvements in depression. This method found that clinical benefits of TMS in depression are due, at least in part, to the functional connectivity of the left DLPFC with the limbic system \[[@REF17]-[@REF19]\].

TMS is regarded as an effective and safe stimulation technique. However, it has a few side effects that might affect treatment compliance. Commonly reported adverse effects include transitory and/or recurrent headaches that respond to over the counter analgesics, a tingling sensation on the scalp and face, and ipsilateral lacrimation. Seizure activity is rare, and one patient was reported to develop trigeminal autonomic cephalalgia after the administration of rTMS for refractory depression \[[@REF20]\].

Conclusions
===========

The clinical efficacy of TMS as an antidepressant has been well established. TMS is an innovative and promising treatment modality for patients with TRD. Patient compliance, however, may be affected, as TMS requires frequent visits to the clinic. Neuromodulation through TMS may induce neurogenesis. Further research is required to explore its therapeutic implementation and limitations, providing more effective treatment of patients with TRD.
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